Distribution of clinical and laboratory features of 32 patients with anti-β2-glycoprotein antibodies of high, heterogeneous, or low avidity
| Anti-β2-GPI avidity | High (n = 6) | Heterogeneous (n = 14) | Low (n = 12) | p Value |
|---|---|---|---|---|
| *According to the criteria for APS. | ||||
| †According to the criteria for SLE. | ||||
| ‡High versus low. | ||||
| §High + heterogeneous v low. | ||||
| ANA, antinuclear antibody; anti-β2-GPI, anti-β2-glycoprotein; APL, antiphospholipid antibody; ENA, extractable nuclear antigen; SLE, systemic lupus erythematosus. | ||||
| No (%) | No (%) | No (%) | ||
| APS*† | 5 (83) | 8 (57) | 5 (42) | <0.05‡ |
| Primary APS* | 2 (33) | 2 (14) | 2 (17) | NS |
| SLE+APS*† | 3 (50) | 6 (43) | 3 (25) | NS |
| SLE+aPL† | 1 (17) | 6 (43) | 7 (58) | <0.05‡ |
| Skin† | 3 (50) | 7 (50) | 7 (58) | NS |
| Arthritis† | 4 67) | 9 (64) | 5 (42) | NS |
| Serositis† | 2 (33) | 5 (36) | 3 (25) | NS |
| Renal disease† | 3 (50) | 7 (50) | 2 (17) | <0.05§ |
| Central nervous system† | 3 (50) | 3 (21) | 2 (17) | NS |
| Haematological disease† | 3 (50) | 9 (64) | 7 (58) | NS |
| Immunological disorder: | ||||
| ANA (⩾1:320)† | 4 (67) | 10 (71) | 7 (58) | NS |
| Ro/La | 0 | 8 (57) | 5 (42) | <0.05‡ |
| Other ENA | 1 (17) | 3 (21) | 3 (25) | NS |
| Thrombosis* | 5 (83) | 7 (50) | 4 (33) | <0.05‡ |
| Arterial | 2 (33) | 1 (7) | 2 (17) | NS |
| Venous | 2 (33) | 2 (14) | 0 | <0.02‡ |
| Microvascular | 1 (17) | 4 (29) | 2 (17) | NS |
| Obstetric disorder (n = 30)* | 2/4 (50) | 3/14 (21) | 3/12 (25) | NS |
| Livedo reticularis | 2 (33) | 2 (14) | 1 (8) | NS |
| Thrombocytopenia | 0 | 3 (21) | 0 | NS |
| Valvar disease | 1 (17) | 3 (21) | 2 (17) | NS |